EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC-ND 4.0

Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System ( SNDS )

A Havet iD, C Bouvard iD, A Moskal iD, M Chanelière, J Massardier, B Lebrun-Vignes iD, A-P Jonville-Bera iD, C Payet, M Viprey iD

Journal of the European Academy of Dermatology and Venereology · 2025

DOI: 10.1111/jdv.20073 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2025. Verfasst von A Havet und 8 weiteren Autor:innen. Beteiligte Einrichtung: Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France. Hauptthemen laut MEDLINE: Isotretinoin, Dermatologic Agents, Acne Vulgaris, Patient Compliance. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Agence Nationale de Sécurité du Médicament et des Produits de Santé.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Despite the French pregnancy prevention program (PPP), a considerable number of pregnancies are potentially exposed to oral isotretinoin. New measures were taken by the French Medicines Agency, including the restriction of initial isotretinoin prescriptions to dermatology specialists in May 2015 and a new information campaign on teratogenicity in January 2019.

Objectives

The aims were to: describe, between 2014 and 2021, compliance with PPP recommendations: isotretinoin use as a second‐line treatment, first prescription by a dermatology specialist, monthly prescription renewal and pregnancy testing (PT); assess the effect of the 2015 and 2019 measures on PT compliance; and identify the determinants of PT noncompliance.

Methods

A retrospective cohort study was conducted among women aged 11–50 years initiating isotretinoin between 2014 and 2021 using the French Health Data System. PT compliance corresponded to pregnancy test completion and specific delays between prescription and dispensation. Time series analyses were performed to evaluate the effect of the 2015 and 2019 measures on PT compliance, and log‐binomial and Poisson multivariate regression models were used to identify the determinants of PT noncompliance.

Results

Isotretinoin was prescribed as a second‐line treatment in 64% of initiations, mainly by dermatology specialists (92%). A new monthly prescription was observed in 98% of dispensations. PT compliance reached 61%, 72% and 25% at initiation, renewals and end of treatment, respectively. The 2015 measure was associated with better PT compliance at initiation and renewals. The 2019 measure had no significant effect on PT compliance at the initiation or end of treatment but was associated with a decrease in PT compliance at renewals. Age, low socioeconomic level, initiation by a nondermatology specialist and during summer were associated with PT noncompliance.

Conclusions

Understanding factors associated with PT noncompliance could help to target specific subpopulations of women treated with isotretinoin.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IsotretinoinDermatologic AgentsAcne VulgarisPatient ComplianceHumansFemaleFranceAdultAdolescentPregnancyRetrospective StudiesYoung AdultChildMiddle AgedCohort Studies

Substanzen

IsotretinoinDermatologic Agents

Autor:innen und Institutionen

  • Research on Healthcare Performance (RESHAPE), INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
  • Hospices Civils de Lyon, Service Des Données de Santé, Lyon, France.
  • Collège Universitaire de Médecine Générale, Université Lyon 1, Villeurbanne, France.
  • Service de Gynécologie-Obstétrique, Hospices Civils de Lyon, Hôpital Femme-Mère-Enfant, Lyon, France.
  • Service de Pharmacologie, Centre Régional de Pharmacovigilance, Hôpital Pitié-Salpêtrière, AP-HP, GH Sorbonne Université, Paris, France.
  • Centre Régional de Pharmacovigilance, CHRU de Tours, Hôpital Bretonneau, Tours, France.

ORCID-Profile: A Havet, C Bouvard, A Moskal, B Lebrun-Vignes, A-P Jonville-Bera, M Viprey

Förderung

  • Agence Nationale de Sécurité du Médicament et des Produits de Santé

Zitieren

APA

Havet, A., Bouvard, C., Moskal, A., Chanelière, M., Massardier, J., Lebrun-Vignes, B., Jonville-Bera, A. P., Payet, C., & Viprey, M. (2025). Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System ( SNDS ). Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.20073

Vancouver

Havet A, Bouvard C, Moskal A, Chanelière M, Massardier J, Lebrun-Vignes B, et al. Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System ( SNDS ). Journal of the European Academy of Dermatology and Venereology. 2025. doi:10.1111/jdv.20073

BibTeX
@article{Havet2025,
  author = {Havet, A and Bouvard, C and Moskal, A and Chanelière, M and Massardier, J and Lebrun-Vignes, B and Jonville-Bera, A-P and Payet, C and Viprey, M},
  title = {Compliance with the pregnancy prevention program among women initiating isotretinoin treatment between 2014 and 2021: A nationwide cohort study on the French Health Data System ( SNDS )},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2025},
  doi = {10.1111/jdv.20073}
}
Kostenlos starten →